doses of exenatide on glycemic control andsafety and tolerability over a 28-day period inpatients with type 2 diabetes, when added toeither diet modification and exercise alone ormetformin monotherapy, with b.i.d. dosingprior to morning and evening meals. The im-pact of pre-existing therapeutic regimen (dietand exercise alone versus metformin) on exen-atide’s effects was also investigated. STUDY DESIGN AND METHODS Study design This Phase 2, randomized, triple-blind (with respect to subject, investigator, and sponsor),placebo-controlled, multicenter, dose–response clinical trial was designed to evaluate the ef-fects of exenatide over 28 days on hemoglobinA 1c(HbA 1c), fasting plasma glucose (FPG), and